JTX-8064 is under clinical development by Concentra Biosciences and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how JTX-8064’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JTX-8064 is under development for the treatment of cold tumor including naïve platinum resistant ovarian cancer, head and neck squamous cell carcinoma (HNSCC), extrahepatic bile duct cancer, gallbladder cancer, undifferentiated pleomorphic sarcoma (UPS) and liposarcoma (LPS), non-small cell lung cancer (NSCLC), renal cell carcinoma (ccRCC), triple negative breast cancer (TNBC), cutaneous squamous cell carcinoma (cSCC). It acts by targeting LILRB2 (leukocyte immunoglobulin-like receptor subfamily B member 2). The drug candidate is developed based on translational science platform. It is administered through intravenous route.
Concentra Biosciences overview
Concentra Biosciences is a bioscience company that develops novel immunotherapies for the treatment of cancer. The company is headquartered in San Diego, California, the US.
For a complete picture of JTX-8064’s drug-specific PTSR and LoA scores, buy the report here.